-+ 0.00%
-+ 0.00%
-+ 0.00%

Mira Pharmaceuticals' SKNY-1 reduces weight in obese mice in pilot study

PUBT·10/29/2026 12:14:28
Mira Pharmaceuticals' SKNY-1 reduces weight in obese mice in pilot study
  • MIRA Pharmaceuticals today reported initial pilot-study results showing oral obesity candidate SKNY-1 reduced weight and fat in obese mice versus vehicle controls.
  • Weight reduction occurred without a significant decrease in food consumption, suggesting a potential metabolic effect beyond appetite suppression.
  • SKNY-1 showed no significant lean-mass loss versus vehicle controls, while semaglutide-treated mice showed significant loss.
  • During two weeks following treatment cessation, SKNY-1-treated mice had limited weight regain, compared with rapid, substantial rebound in the semaglutide group.
  • Longer-term preclinical studies will assess weight reduction, body composition and metabolic effects to support future clinical development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290800PRIMZONEFULLFEED9855413) on October 29, 2026, and is solely responsible for the information contained therein.